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Abstract 
 It has previously been shown that effective probiotics can accelerate gut maturation and 
the development of a normal microflora in poultry. This results in increased resistance to enteric 
pathogens encountered by chicks early in life. Our objective in experiments 1 and 2 was to 
evaluate the effect of in ovo administration of FloraMax®-B11 (FM) on Marek’s disease (MD) 
herpesvirus of turkeys (HVT) vaccine protective efficacy. In Exp. 1, day 18 White Leghorn 
embryos were randomly distributed in four groups, 1) HVT vaccinated, no MDV challenge, 2) 
HVT + FM vaccinated, no MDV challenge, 3) HVT vaccinated, challenge with virulent MDV, 
4) HVT+ FM vaccinated, challenge with virulent MDV. Exp. 2 was designed the same as Exp. 1, 
except chicks were challenged with a very virulent MDV strain. There was no significant 
difference (P> 0.05) in MD incidence between birds vaccinated with and without FM in the HVT 
vaccine. In Exp. 3 and 4, day 18 commercial broiler embryos were in ovo injected with either 
saline or FM to measure hatchability, microbiota composition, morphometric analysis, and 
Salmonella enterica serovar Enteritidis (SE) infection in chickens. The administration of the 
probiotic did not negatively affect hatchability, but significantly reduced (P<0.05) coliforms 
within the gut. In Exp. 4, the FM treated group showed significantly increased (P<0.05) BW at 7 
days when compared to the controls. This is associated with the higher villi surface area 
observed in the FM group and reduced (P<0.001) SE incidence and (P<0.05) CFU recovery. The 
results of these studies suggest that the in ovo administration of FM into the amnion at 18 days of 
embryogenesis does not impact the protection of the HVT vaccine against MD or negatively 
affect hatchability. It also reduces the recovery of gram negative bacteria, improves BW during 
the first 7 days, and decreases SE recovery in broiler chickens.                 
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Chapter I. Introduction 
 Until recently, antibiotics have long been used in the poultry industry. They have been 
used to stimulate growth rate and feed efficiency and to control pathogenic bacteria. The 
growing concern of antibiotic resistant bacterial strains and residues in food have caused 
regulatory agencies and producers to reduce and even abandon the use of antibiotics. This 
pressure has stimulated a need for viable alternatives to the antibiotics. A very promising 
alternative is the use of probiotics. Due to this, there has been a recent surge in probiotic 
development with encouraging results. However, in a commercial setting, chicks will not be able 
to receive the beneficial bacteria until being placed in the chicken houses, where they can receive 
it in the water or feed. Prior to this, chicks are exposed to the contaminated air within the hatch 
cabinets and usually long, stressful transportation to their destinations. This allows pathogenic 
bacteria to colonize and delay gut maturation and health within the newly hatched chick. In 
poultry, there is a way to administer the probiotic before the chicks hatch. At Day 18 of 
embryogenesis, almost all broilers are vaccinated for Marek’s Disease virus (MDV). This thesis 
addresses the testing of a commercial probiotic and its ability to be administered with the 
Marek’s vaccine, its effect on hatchability, and gut development and composition.   
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Chapter II. Literature Review 
Transfer of Microflora 
 The gut microbiota plays an important role in health by providing a barrier for 
colonization of pathogens, by utilizing important metabolic functions (fermentation of 
nondigestible fibers, production of short-chain fatty acids, and vitamin supplementation), and by 
stimulating the development of the immune system (Guarner and Malagelada, 2003). At birth, 
animals receive a natural inoculation of microbes, which establish themselves in the intestines. 
This colonization of beneficial microflora allows the animal to resist potential environmental 
challenges. In mammals, the inoculation occurs during parturition, with bacteria living in the 
vaginal mucus, and through breast feeding (De Oliveira et al., 2014). Neonate gastrointestinal 
tracts are sterile at birth, but the microorganisms near the vagina or anus of the mother rapidly 
colonize the neonate after birth (Phillips et al., 2004). Within a few hours, bacteria begins to 
appear in the feces. It is suggested that the gastrointestinal tract is first colonized by facultative 
aerobes due to the intestinal environment showing a positive reduction potential at birth. As 
these microbes consume oxygen, the environment transfers to a negative reduction potential and 
allows the growth of strict anaerobes (Bezirtzoglou, 1997).  
 As stated earlier, during the first days of life, the bacteria colonizing the infant 
gastrointestinal tract come primarily from the mother and the environment. For this reason, one 
of the biggest determinants of the pioneer colonizers is the mode of delivery (Penders et al., 
2006). Infants born vaginally, are first colonized by the fecal and vaginal bacteria of the mother, 
whereas cesarean section born infants are first exposed to bacteria in the hospital environment 
and health care workers (Bezirtzoglou, 1997; Gronlund et al., 1999). Studies have shown vaginal 
delivery at home resulted in higher colonization rates and counts of Bifidobacteria and 
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Bacteroides fragilis-group species and reduced incidence and counts of Clostridium difficile and 
Escherichia coli when compared with cesarean section (Penders et al., 2006). The timing of 
colonization and difference of bacterial populations between the two delivery methods can 
persist for months or even the whole life of the individuals (Schultz et al., 2004; Rao et al., 
2009). Unfortunately, cesarean born infants are also usually more susceptible to intestinal 
disorders (Gronlund et al., 1999; Penders et al., 2006; Cochetiere et al., 2007).   
  In birds, colonization occurs in nests through contact with brooding hens and nesting 
materials (Mills et al., 1999). In modern poultry production, there is no contact between chicks 
and hens, and chicks are first exposed to bacteria in the hatchery and chicken house environment. 
Artificial incubation of poultry eggs has been shown to delay the colonization of beneficial 
microflora due to the lack of interaction with adult birds (Hashemzadeh et al., 2010).     
Gastrointestinal Tract 
 The GIT serves as the interface between the diet and the metabolic events that sustain 
life. It is also the largest immune organ in the body, and serves as a barrier for prevention of 
infection (Abreu-Martin and Targan, 1996; Mayer, 2000). The avian mucosal immune system 
contains M cells, plasma cells, T cells, macrophages, intraepithelial lymphocytes, and heterophils 
(Erickson and Hubbard, 2000). In poultry, a crucial factor in digestion and absorption of 
nutrients are the intestinal villi, which are underdeveloped at hatch (Uni et al., 1995) and not 
fully developed until 10 days of age (Noy and Sklan, 1997). As birds hatch, they must transition 
from energy supplied via endogenous nutrients of the yolk to exogenous carbohydrate rich feed. 
During this transition, significant changes occur both in morphology and intestinal size (Uni et 
al., 1995). This maturation of the gut also affects the epithelial cell membranes, which are a 
major mechanical barrier between the internal environment of the host and the external foreign 
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material in the lumen (Rozze et al., 1982). By dietary means, it is possible to affect the 
development of the gut and the competitiveness of both beneficial and harmful bacteria, which 
can alter not only gut dynamics, but also many physiological processes due to the end products 
metabolized by symbiotic gut microflora. Within the mucous layer, tight junctions between 
epithelial cells and gut-associated lymphoid tissue help to maintain a homeostasis between 
dietary antigens, in addition to enteric pathogens and beneficial microorganisms (Vicuna et al., 
2015). Dysbiosis within the gut, opens tight junctions which reduces barrier function, resulting in 
nonselective permeability. This could lead to malabsorption of nutrients and translocation of 
possible pathogenic enteric bacteria to various internal organs, which could result in disease and 
reduced growth performance (Quinteiro-Filho et al., 2012). Recent poultry research has shown 
that leakage of enteric bacteria into circulation results in non-gastrointestinal diseases (Tellez et 
al., 2009; Borst et al., 2012; Wideman, 2013).    
Microflora of the Gastrointestinal Tract 
Naturally, animals are colonized by microorganisms that form a specific ecological 
community of commensal, symbiotic, and pathogenic microorganisms or microbiota. Within this 
microbiota, there are both permanently colonizing species and temporary colonizing species that 
are characterized by a number of environmental microorganisms (Fiebiger et al., 2016). Warm 
blooded vertebrates gastrointestinal (GI) tract constitutes one of the most densely populated and 
diverse ecosystems known. The human GI tract’s microflora surpasses the number of cells in the 
body ten-fold and the total mucosal surface area is up to 300 m2. This makes it the largest area of 
the body interacting with the environment and it is colonized with over 1014 micro-organisms 
(Lu et al., 2003; Bjorksten et al., 2006). For this reason, the gut microbiota are the most 
important source of microbial stimulation and the driving force behind the postnatal maturation 
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of the immune system (Bjorksten et al., 2006). Since the GI tract contains such a large number of 
diverse microbes that can be commensal or pathogenic, they affect the host’s nutrient utilization 
and intestinal development either positively or negatively (Dumonceaux et al., 2006).  
A more complete understanding of the microbial ecology of the chicken intestinal 
microbiome is necessary to reduce enteric disease and pathogens of public health concern. 
Studies have shown that bacterial diversity and numbers vary throughout different sections of the 
GI tract (Yegani and Korver, 2008). According to Donoghue et al (2007), it is estimated that 
more than 500 bacterial species inhabit the poultry GI tract, however it is believed only 20% to 
60% have been recovered by traditional culture methods (Lu et al., 2003). In the cecum, the most 
abundant 16s rDNA sequences were homologous to Clostridiaceae at 65.6%, according to Lu et 
al (2003). Conversely, Streptococci (Barnes et al., 1972) and Eubacterium (Salanitro et al., 1974) 
have also been described as the most abundant sequences of bacteria in the cecum of broiler 
chickens. In more recent studies, Ruminococcus, Lactobacillus, and Bacteroides were the most 
predominant genera in the global sequence data set and in two 454 pyrosequencing studies (Qu 
et al., 2008; Stanley et al., 2012a). However, Callaway et al. (2009) found Bacteroides and 
Prevotella to be the most predominant genera in the chicken cecum and Nordentoft et al. (2011) 
found Butyricimonas and Fecalibacterium were predominant. It is believed that differences in 
host, feed, and analysis techniques might all contribute to the differences observed (Wei et al., 
2013).  
 There are few studies on the microbiome of populations within the small intestine of the 
chicken gastrointestinal tract, as most have focused on the cecum. When Lu et al (2003) 
sequenced microbiota of the small intestine, they found that the dominant bacteria in the ileum 
was Lactobacillus. As chickens mature, microbial populations do change slightly, but of the 16s 
6 
 
RNA sequences 70% belonged to Lactobacillus. It has also been shown that lactobacilli were the 
main bacteria present in the duodenum and small intestine, and were also the only bacteria 
present at a level above 104 CFU per gram by culture techniques (Barnes et al., 1972). Another 
study that compared conventional or organic production conditions, also found that Lactobacillus 
was the predominant bacteria present in the ileum of 42 day old broilers regardless of the 
production setting (Bjerrum et al., 2006). Cressman et al. (2010) discovered that at day 7, fresh 
litter chicks ileal mucosa was comprised of mainly Lactobacillus, followed by Lachnospiraceae 
and Enterococcus. Whereas the ileal mucosa of chicks reared on reused-litter was primarily 
colonized by bacteria within the order Clostridiales. Interestingly, in the reused litter, 
Lactobacillus was more predominant in the ileum than in the fresh litter chicks. By day 42, the 
fresh-litter birds had a microbiota similar to the reused-litter birds, which suggests diminishing 
environmental effects, as intestinal bacteria from the excreta accumulates in the litter.        
Concept of Competitive Exclusion 
Metchnikoff (1908) first introduced the idea that intestinal microflora played a role in the 
maintenance of health, when he studied lactic acid bacteria from fermented milk products. He 
observed that Bulgarians who ate significant amounts of yogurt were more resistant to enteric 
infections (Patterson and Burkholder, 2003). He hypothesized that the lactic acid bacteria in the 
yogurt was providing this protection, and that the beneficial nature of these bacteria led to 
prolonged life. The term Competitive Exclusion (CE) was first used by Greenberg (1969), where 
he observed a species of bacteria outcompete another species for receptor sites in the intestinal 
tract, in an article on the exclusion of Salmonella typhimurium from maggots of blow flies. He 
discovered that without the reduction or elimination of normal intestinal microflora the S. 
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typhimurium would not survive. Later, in 1971, van der Waaij and investigators while studying 
pathogen colonization in mice, coined a synonymous term “colonization resistance”.      
Competitive Exclusion 
Competitive Exclusion has proven to be the best alternative route to control disturbances 
within the intestines in poultry. Research worldwide was stimulated by an article in Nature in 
1973 by Nurmi and Rantala, where they tried to control a Salmonella Infantis outbreak in broiler 
flocks (reviewed by Schneitz, 2005). They revealed chicks were most susceptible to Salmonella 
infections during the 1st week of life. They suggested this was due to the delayed establishment 
of normal gut microflora in chicks raised in modern industry production methods. When a 
Lactobacillus strain offered no protection, they decided to assess the effectiveness of CE, a 
population of intestinal bacteria from adult chickens that were resistant to the S. infantis. They 
administered the mixed culture orally and were able to achieve adult type resistance to 
Salmonella (reviewed by Edens et al., 1997). Rantala and Nurmi (1973) recognized that 
inoculating young chickens with unidentified GI tract contents could possibly cause a pathogen 
to be introduced. So, cecal contents from healthy adult chickens were grown anaerobically and 
passed three times prior to inoculating the chicks. The passages were intended to allow time to 
check for specific pathogens and also to minimize the risk of pathogens in the culture. In their 
experiment, day old chicks were treated with the passaged cecal content, diluted rumen content, 
diluted fresh horse feces, or diluted crop and cecal contents of healthy adult chickens. The chicks 
were then challenged 24 h post treatment with 103 Salmonella Infantis. All chicks receiving 
chicken microflora tested negative for Salmonella, while all chicks receiving different species 
bacteria were positive for Salmonella. From this study, it was demonstrated that the passaged 
culture was as efficacious as the unpassaged and that there is host specificity because only the 
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chicken cecal microflora were able to protect the chickens, unlike the horse or cattle feces 
(Rantala and Nurmi, 1973).      
Mechanism of CE 
 There are four major proposed mechanisms of CE: 1) creation of microecology that is 
hostile to other bacterial species, 2) elimination of available bacterial receptor sites, 3) 
production and secretion of antimicrobial metabolites, and 4) selective and competitive depletion 
of essential nutrients (Rolfe, 1991).  
The determining factor in the viability of microorganisms is the microecology of the 
intestinal tract. Meynell (1963) determined that the production of volatile fatty acids at a pH 
below 6.0 will decrease populations of Salmonella and Enterobacteriacea. The mechanism of 
CE can be eliminated by use of antibiotics causing disruptions within the normal intestinal 
microbial populations. This causes concentrations of volatile fatty acids produced by intestinal 
bacteria to decrease, allowing for gut pH to increase to a more alkaline state (Edens et al., 1997). 
It has been shown, in newly hatched chicks that the volatile fatty acid concentration and pH are 
not adequate enough to chemically exclude pathogens (Barnes et al., 1979, 1980a,b).  
 In order for the host to be at risk to pathogens attaching to the intestinal epithelium, it is 
required for there to be accessible sites for adhesion. According to Soerjadi et al. (1982), this 
attachment is facilitated through the polysaccharide-containing components attached to the cell 
wall. This component blocks all receptor sites by binding bacteria to each other and the 
epithelium.  
 The antimicrobial substances produced and secreted by the endogenous bacteria of the 
intestinal tract can either kill or inhibit growth of pathogens (Rolfe, 1991). Research has shown 
that Lactobacillus as a group, produced significant amounts of bacterial growth inhibitory 
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substances (Edens et al., 1997). Talarico et al. (1988), revealed that the secretion of reuterin, by 
L. reuteri had broad-spectrum killing capabilities within the intestinal tract of chickens.  
 The fourth mechanism, competition for available nutrients as a means to control intestinal 
bacteria, is probably not the most effective means for CE. There are many environmental factors 
that enhanced the availability of nutrients from the diet of the host or through manipulation of 
dietary ingredients, favored the growth of certain populations (Rolfe, 1991). This could result in 
the exclusion of other bacterial species. Casas et al. (1993) showed that influencing the lactose 
concentration in the diet of chicks and poults, we can selectively provide an advantage for the 
enhancement of L. reuteri.  
Probiotics 
 The use of selected beneficial lactic acid bacteria as probiotics has been suggested for 
many years due to their ability to prevent various enteric diseases and improve overall health 
(Tellez et al., 2006). In 2006, the European Union banned the use of antibiotics as feed 
supplements and recent concern in the United States has resulted in consumer’s requesting 
antibiotic free chicken. This pressure has generated the need to find alternative options to the use 
of antibiotics in the feed. A very promising alternative is the use of probiotics (Higgins et al., 
2005; Wolfenden et al., 2010; Barbosa et al., 2005).  
   The definition of probiotics according to the FAO/WHO (2001), is “live 
microorganisms which, when administered in adequate amounts, confer a health benefit on the 
host.” Probiotics have been used to treat intestinal disorders and improve intestinal health (Aureli 
et al., 2010; Nicholson, 2002). In poultry, probiotics are used to supplement beneficial 
colonization of the intestines in chicks after hatch (Fuller, 2001). They are also used to increase 
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broiler performance (Lutful Kabir, 2009) and control the incidence of pathogens (La Ragione & 
Woodward, 2003).  
 Patterson & Burkholder (2003) described ideal probiotics as, non-pathogenic, of host 
origin, resistant to gastric and bile acids, ability to persist in the gastrointestinal tract, produce 
antimicrobial substances, adhere to epithelium, modulate immune response, and tolerate 
processing and storage. The most common types of probiotic bacteria are lactic acid bacteria, 
such as Bifidobacterium spp., Lactobacillus spp., and Enterococcus spp. (Ljungh & Wadstrom, 
2006). Lactic acid bacteria are Gram-positive bacteria that ferment carbohydrates into lactic acid 
and energy. These bacteria are normally found within the gastrointestinal tract of humans and 
animals. The most common LAB used as a probiotic is the genus Lactobacillus, a Gram-positive, 
catalase negative, nonspore-forming, and facultative anaerobe. According to Hori (2010), there 
are currently more than 125 identified Lactobacillus species.   
Immunomodulation 
  Normal microflora of the GI tract is crucial for priming the immune system (Gaboriau-
Routhiau, 2001), possibly due to beneficial, probiotic-type bacteria that are believed to modulate 
the immune response (Christensen et al., 2003). Animals lacking normal microflora experience a 
diminished degree of response to immune stimulus. It has been shown that germ-free animals 
produce as little as one third of the normal antibody-producing B cells as conventional animals 
(Mitsuoka, 1978). Intestinal bacteria are essential for the development of gut-associated 
lymphoid tissue (GALT), which is important in the immune functions of the epithelium and the 
development of the normal antibody repertoire. Commensal bacteria can be killed by enteric 
macrophages, but survive within underlying dendritic cells of the gastrointestinal tract 
(Macpherson and Uhr, 2004). These bacteria are presented to B cells in the mesenteric lymph 
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nodes which allows for an immune response of IgA. These dendritic cells also respond 
differently to the normal commensal bacteria as opposed to potentially pathogenic ones. They 
secrete different cytokines or are unresponsive, likely due to the expression of different toll-like 
receptors on the differentiated dendritic cells (Christensen et al., 2003; Karlsson et al., 2004).  
Stimulation of the innate immune system allows for improved acquired immune 
responses through better antigen presentation (Chin and Mullbacher, 2003). Clinical studies have 
reported a negative correlation between infectious disease and the presence of lactobacilli 
(Alvarez-Olmos et al., 2004) and probiotic bacteria have been shown to increase the humoral and 
cellular immune response against E. Coli (Miettinen et al., 1998) and Salmonella enterica 
serovar Enteritidis (Koenen et al., 2004). It is possible that effects Lactobacillus have on the 
immune system is contributed to secreted signaling molecules and not necessarily the presence 
of the bacteria, as Lee et al (2004) showed an increase in T, NK, and MHC-II cells after several 
administrations of cytoplasmic lactobacilli extracts.   
It has been shown that inflammatory responses in the GIT are reduced by some 
commensal, non-pathogenic bacteria (Drakes et al., 2004). This is explained by probiotic bacteria 
inducing the expression of anti-inflammatory cytokines such as IL-10 and reducing the 
expression of pro-inflammatory IL-1 (Lammers et al., 2003). With the increased expression of 
cytokines that do not induce inflammation and the increased expression of MHC-II, it is possible 
for the immune response to have a higher secretion of antibodies (Abbas et al., 2000).  
Studies have shown that probiotics significantly increased antibody production in broilers 
(Kabir et al., 2004) and that antibody titer in probiotic treated birds was significantly higher post 
immunization of SRBC when compared to the controls (Khaksefidi and Ghoorchi, 2006). It has 
also been demonstrated, that administration of probiotics enhances serum and intestinal natural 
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antibodies to several foreign antigens in chickens (Haghighi et al., 2005). Dalloul et al. (2005) 
studied the effects of the intestinal immune response to an Eimeria Acervulina infection when 
Lactobacillus-based probiotics were supplemented in the feed. It was reported that the probiotic 
afforded some measure of protection through immune modulation. The early immune response 
was stimulated by the probiotic, characterized by early IFN-γ and IL-2 secretions which 
improved local immune defenses against coccidiosis.  
  
FloraMax 
 The commercial probiotic FM-B11 (FloraMax®) is a defined 11-isolate LAB culture of 
the genus, or related to, Lactobacillus. This product was used in a field trial with 234,105 
broilers in Mexico (Vicente et al., 2007). The birds treated with FM-B11 showed a 2.06% 
improvement in bodyweight, a 3.5% improvement in feed conversion, and a .9% reduction in 
mortality when compared to the controls. The same probiotic was used in a commercial turkey 
field trial where they reported increases in average daily gain and body weight of 1.63g and 190g 
respectively over untreated controls. The costs of production were also compared between the 
treated and untreated groups and the cost per kilogram of meat was reduced by $0.0153 in the 
probiotic treated group (Torres-Rodriguez et al., 2007).  
A study was performed to evaluate the efficacy of typical prophylactic antibiotic use 
compared with the use of probiotics, or a combination of both in turkey brooding houses deemed 
likely to experience an outbreak of idiopathic diarrhea (Higgins et al., 2005). In the experiment, 
the poults receiving FM-B11 periodically in the drinking water had significantly higher mean 
body weights than the control group and numerically higher weights than the other probiotic 
group and antibiotic groups. In another experiment, the poults were experiencing a severe 
13 
 
Salmonella Senftenberg infection and were administered FM-B11 or antibiotics plus another 
probiotic. Between d 12 and 47 the poults receiving the antibiotic and other probiotic gained 
significantly more weight than FM-B11 alone or the untreated controls. However, weight gain at 
the end of the experiment between d 29 and 47 no differences in BWG across all treatments were 
reported. (Higgins et al., 2005).   
Higgins et al. (2007) evaluated the ability of FM-B11 to reduce the amount of 
recoverable Salmonella from the ceca of broiler chicks. In their first 3 experiments, the 
administration of the probiotic 1 hour post Salmonella enterica serovar Enteritidis or Salmonella 
Typhimurium challenge significantly reduced the incidence of Salmonella recovery, 60-70% and 
89-95% respectively, from the cecal tonsils when compared to the control group, 24 hours post 
treatment. They also observed a 2.9 log10 reduction in Salmonella enterica serovar Enteritidis 
recovery from probiotic treated birds when compared to the controls, 24 hours post treatment. In 
the next 4 experiments, FM-B11 again significantly reduced cfu recovery 24 hours post 
treatment, the probiotic also reduced cfu recovery at 12 hours post treatment, even though there 
was no difference in incidence. FM-B11 was also shown to reduce Salmonella enterica serovar 
Enteritidis. The encouraging data collected from FM-B11 administration resulted in a 
commercial product that is currently used in the poultry industry.     
Marek’s Disease 
Marek’s disease (MD) is one of the most widespread avian diseases and can be found in 
chicken flocks worldwide. The disease was first recognized by Jozsef Marek, a Hungarian 
veterinarian in 1907 (Sluis, 1997). It is a highly contagious disease caused by a herpes virus and 
is identified by the presence of lymphoid tumors in various organs (Okazaki et al., 1970). This 
airborne pathogen costs the poultry industry $1-2 billion annually (Morrow and Fehler, 2004), by 
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causing paralysis, condemnations and high mortality due to T cell lymphomas and peripheral 
nerve damage (Reddy et al., 1996). The disease may survive for months or years in the litter or 
poultry dust. Since the virus is inhaled, infection occurs through the respiratory tract and infected 
birds continue to be carriers long after their infection. Chickens are usually infected at an early 
age, however lesions are normally not seen until 8-24 weeks of age. At first, all attempts of 
isolation, sanitation, and genetic resistance to protect flocks from the disease were mostly 
unsuccessful.  
Over the past 40 years, the poultry industry has depended on a series of avirulent or 
attenuated live virus vaccines to provide protection against field strains of Marek’s disease in 
chickens (Calnek, 2001). These vaccines are the first effective practical means for the control of 
any neoplastic disease in man or animals. Marek’s disease virus-1 (MDV1) causes the condition 
known as MD in chickens (Churchill and Biggs, 1967). Herpes virus of turkeys (HVT/MDV3) 
and MDV2 are naturally occurring, infectious viruses that are apathagenic and non-oncogenic in 
chickens, and are used as vaccines against MD either separately or in combination (Witter et al., 
1970). Viruses from all three serotypes have been used as cell-associated live vaccines. In the 
1970s, the HVT vaccine provided tremendous protection for a short period of time, until there 
was a decline in the efficacy of monovalent HVT vaccine due to interference from homologous 
maternal antibodies and to the development of MDV field strains of increased virulence. By the 
1980s, a bivalent vaccine composed of a mixture of HVT and the serotype 2 strain SB-1 was 
introduced. This vaccine offered better protection than either of the individual components used 
alone, a well-known phenomenon protective synergism (Witter and Lee, 1984). As field viruses 
continued to increase in virulence, the attenuated serotype 1 strain CVI988 known as Rispens 
vaccine was implemented for extensive use in the 1990s (Rispens et al., 1972). The CVI988 is 
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still the most widely used vaccine and is the most protective due to being a serotype 1 and the 
most closely antigenically related to field strains (Baignet, 2006). 
The vaccines establish a persistent infection which helps to reduce early viremia, after 
exposure to pathogenic strains. It also protects against tumor formation and mortality which 
takes away economic consequences due to infection (Morimura et al., 1998). MDV vaccines 
however, do not prevent super-infection due to challenge viruses. The challenge virus still 
multiplies and sheds from feather tissues and is oncogenic to non-vaccinated birds. The selection 
pressure forced on these virulent viruses in vaccinated birds is instigating evolution of field 
viruses towards pathotypes of greater virulence (Witter, 1997). Even though current vaccines are 
effective, an ideal vaccine would prevent replication of the virus or shedding.  
Inoculation of the vaccine into day-old chicks is followed by replication of the virus a 
few days later in the lymphoid organs. Then, the vaccine infected lymphocytes are released into 
the peripheral blood. For optimal protection, the vaccine needs 1-2 weeks between vaccination 
and exposure. This allows the vaccine virus to enter into the latency stage of infection. It is 
believed that there is a two-step mechanism of protection. First, the antigens of the vaccine virus 
are similar to those of the virulent strains and these antigens stimulate an immune response to the 
virulent virus. This results in decreased viremia, viral replication, malignant transformation, and 
immunosuppression (Baignet et al., 2006). The second step is MDV tumor antigens stimulating 
the immunological rejection of tumor cells by cytotoxic T cells (Powell, 1978).  
Vaccines used to be administered to day-old chicks subcutaneously in the neck or 
intramuscularly in the leg using a semi-automated device. This machine relies on the operator to 
correctly press the chicken against the needle to receive the full dose and could only vaccinate up 
to 3,000 birds per hour. Due to this laborious task that cost a lot of time and money, now 
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hatcheries use an in ovo delivery system to administer the vaccine to embryos at transfer from 
the setters to the hatchers (day 18). These machines are equipped with individual floating 
injectors that can adjust automatically for uniform needle depth in eggs of all sizes and 
administer a precise dose to 30,000 eggs per hour. The machine also sanitizes the needles after 
each injection and accurately distinguishes live from infertile or dead embryos and delivers 
vaccine only to viable eggs. With this method, 100% of chicks are correctly vaccinated against 
MDV and the timely administration allows for early and effective stimulation of the immune 
response (Baignet et al., 2006) In 2006, Baignet et al. (2006) reported that a total of 4.2 billion 
layers, 0.5 billion breeders, and 17 billion broilers are vaccinated annually worldwide.  
In Ovo Technology  
 The agriculture industry is reducing and eliminating drug use as growth promoters in 
animal diets. These antibiotic growth promoters were used to control poor intestinal conditions 
caused by dysbacteriosis or parasites, by adding lows doses of the AGP and coccidiostats to 
commercial poultry diets (De Oliveira et al., 2014). Therefore, many alternatives to growth 
promoters are now available (Buchanan et al., 2008; Kim et al., 2011). Preferably, usage of drugs 
in production would be avoided by prevention of diseases rather than treatment. This could be 
achieved by prophylactic administration of probiotics that prevent colonization of pathogens 
(Cukrowska et al., 2002). In poultry, colonization is thought to take place after hatching, 
however there is some evidence from Pedroso (2009) and Bohorquez (2010) that before hatch, 
small numbers of live bacteria can be found in the intestines. Even though probiotics (DFM) are 
often used in the pre-starter and starter diets, chicks can be exposed to pathogenic bacteria within 
the hatchery long before they ever consume any feed (De Oliveira et al., 2014).   
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Fertile eggs from breeder farms can be contaminated with many bacteria that are on the 
shells surface or that have penetrated beneath the shell. This can be from contaminated nesting 
material or the simple fact that a freshly laid, warm, wet egg is highly susceptible to 
contamination from microorganisms (Cox et al., 1991). At hatch, chicks have an unestablished 
microflora in their gut and are highly susceptible to intestinal colonization of enteric pathogens 
within the hatching environment (Cox et al., 1992). Bacteria such as Salmonella and E. coli can 
also penetrate the eggshell and proliferate as incubation conditions similarly favor these 
microorganisms. These bacteria do not usually affect the chick from hatching and consequently 
create widespread bacterial reservoirs within commercial hatcheries (Cox et al., 1990). 
Therefore, the presence and persistence of bacterial contamination within the hatchery implies 
that the susceptible day-of-hatch chicks could be at a greater risk of colonization by pathogenic 
bacteria in the hatchery than during grow-out (Cox et al., 1990). With this knowledge that the 
first microbes the chicks may come into contact with could be pathogenic, it seems intuitive that 
we should not leave pioneer intestinal colonization to chance when we can intentionally 
inoculate with beneficial bacteria (Cukrowska et al., 2002). 
 The concept of in ovo CE was first put forth in the 1990s when chicken embryos were 
inoculated into the air cell membrane (Cox et al. 1992). However, previous attempts of this 
method resulted in practical issues such as higher post hatch mortality and reduced hatchability 
(Cox et al., 1992; Meijerhof and Hulet, 1997). Cox et al. (1992) administered a CE culture from 
1 year old, Salmonella-free caged layers that was grown anaerobically and passed once. Embryos 
were injected onto the air cell membrane or below the air cell membrane. Only the 1:1,000 and 
1:1,000,000 dilutions administered into the air cell resulted in higher hatchability numbers that 
still were not acceptable, 81% and 78% respectively compared to the controls at 96%. The 
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1:1,000 dilution group also acquired resistance to an oral challenge of S. typhimurium (106) at 
day of hatch when compared to the controls. A subsequent experiment demonstrated that dose 
and delivery depth had an effect on chick hatchability (air cell and amnionic fluid).Doses ranging 
from undiluted to 1:1,000,000 of CE culture had a significant negative effect on hatchability. Air 
cell administration reduced hatchability, but chicks showed Salmonella resistance at hatch. 
However, when the CE mixture was administered into the amnionic fluid, the undiluted and 
1:1,000 dilution prevented any hatching, and the 1:1,000,000 dilution hatched less than 50%.  
Edens et al. (1997) were able to successfully apply in ovo Lactobacillus reuterin in the air 
cell and amnion without having negative effects on hatchability. All studies reported since Edens 
(1997) paper have concentrated on in ovo inoculation of different bacteria into the air cell due to 
the work of Cox et al. (1992), however those studies have all had a negative impact on 
hatchability (Meijerhof and Hulet, 1997; Hashemzadeh et al., 2010; Hosseini-Mansoub et al., 
2011; Yamawaki et al., 2013). The reasons these studies saw differences could be due to factors 
such as delivery technique, site of injection (air cell vs. amnion), type of bacteria used, and 
inoculated dose (De Oliveira et al., 2014). These are all vital parameters that must be considered 
in order to successfully inoculate bacteria in ovo. This was demonstrated by De Oliveira et al. 
(2014), where 14 different bacterial isolates were in ovo injected and it was found that some 
strains were lethal regardless of dose and some lethal due to dose. This confirmed results of 
Edens et al. (1997), that there is no reason to avoid amnion inoculation based on hatchability if 
strains are tested for negative effects and adjusted to avoid this issue. Amnion injections are a 
preferred method because it eliminates the complications of other techniques such as, imprecise 
dose reaching the chick by air cell and spraying delivery and practical issues of individual bird 
inoculation of oral gavage and vent lip application (De Oliveira et al., 2014). Due to current in 
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ovo technology, the administration of vaccines, probiotics, and other components should be 
combined into a single dose, given together for individual and precise delivery.        
In ovo vaccination is currently the standard procedure for the application of Marek’s 
disease virus and infectious bursal disease vaccines in the hatchery for broiler chickens in the 
United States (Williams and Zedek, 2010). Newly hatched chicks encounter many antigens 
during the first few days of life, while their immune system is still developing. The highest 
mortality in commercial chickens usually occurs within the first 7 days of life. 
Summary 
 Due to the intense pressure on the poultry industry and the scientific community to find 
alternatives to antibiotics for food producing animals, the industry is in need of a replacement 
therapy for fighting enteric disease in poultry. In commercial poultry, the chicks do not receive 
beneficial microflora from the hen. Instead, the first exposure they have is the contaminated air 
inside the hatch cabinets. This allows for pathogens such as Salmonella or E. coli to have an 
opportunity to be the pioneer colonizers of the developing embryo’s gut. With the surge in 
probiotic development and the promising results that have been observed, if a proper candidate 
probiotic could be administered before hatching, the embryo could be colonized with beneficial 
bacteria before leaving the egg. In poultry, this is possible due to in ovo technology and the 
administration of the Marek’s disease vaccine at day 18 of embryogenesis. This is a promising 
method with commercial application if the right probiotic could be mixed with the vaccine and 
administered together in one package.     
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ABSTRACT 
Four experiments were conducted to evaluate the effect of in ovo administration of FloraMax®-
B11 (FM) on Marek´s disease (MD) herpesvirus of turkeys (HVT) vaccine protective efficacy, 
hatchability, microbiota composition, morphometric analysis and Salmonella enteritidis (SE) 
infection in chickens. In Exp. 1, day 18 White Leghorn embryos were randomly distributed in four 
groups: 1) HVT vaccinated in ovo and no Marek’s disease virus (MDV) challenge; 2), HVT + FM 
vaccinated in ovo and no MDV challenge; 3) HVT vaccinated in ovo and challenge with virulent 
MDV (vMDV; strain 583A); 4), HVT + FM vaccinated in ovo and challenge with vMDV. Exp. 2 
was designed exactly the same as Exp. 1 but chicks were challenged with very virulent MDV 
(vvMDV; strains Md5 and 612). In both experiments, birds were monitored until 8 wk of age, and 
tested for MD incidence. Exp. 3 and 4, day 18 commercial broiler embryos were injected in ovo 
with either saline or FM to measure hatchability and gastrointestinal composition. In addition, in 
Exp. 4, all chickens that hatched were then orally gavaged with SE at hatch and kept for 7 d to 
monitor post hatch BW. In Exp. 1 and 2, there was no significant difference (P > 0.05) between 
% MD in birds vaccinated with HVT alone or HVT + FM. In Exp. 3 and 4, administration of the 
probiotic did not negatively affect hatchability, but did reduce coliforms. Further, increase in BW 
was associated with higher villi surface area in ileum in chickens that received the probiotic as 
well as a significant reduction in the SE incidence. These results study suggest that in ovo 
administration of FM does not negatively impact the ability of HVT to protect against MD or 
hatchability of chickens, and improves BW during the first 7 d of life and decreases SE recovery 
in broiler chickens.  
 
Key words: In ovo, Marek’s disease vaccine, probiotic, chickens, hatchability  
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INTRODUCTION 
Bacterial communities living and colonizing in the gastrointestinal tract of animals outnumber total 
somatic cells of metazoans by an estimated 10-fold (Neish, 2009). Today, the microbiome is 
recognized as the ‘forgotten organ,’ operating like an organ within the host and orchestrating 
numerous physiological and biological functions that have a profound impact on the balance 
between health and disease (O’Hara and Shanahan, 2006; Tellez, 2014). Early establishment of 
the microbiome have been reported to improve the assembly of the gut-associated lymphoid tissue 
(Martin et al., 2010), intervene in the development of the immune system (McFall-Ngai, 2007), 
maintain mucosal barrier integrity (Duerkop et al., 2009), modulate proliferation of enterocytes 
(Moran, 2007), adjust blood flow (Sekirov et al., 2010), regulate the enteric nervous system 
(Tlaskalová-Hogenová et al., 2011), and improve digestion of nutrients (Dass et al., 2007; Walter 
et al., 2011; Qiu et al., 2012). Essential colonization of these bacterial populations starts at 
birth/hatch, and is followed by progressive assembly of a complex and dynamic microbial society 
(Di Mauro et al., 2013).  
Under commercial conditions, millions of chickens and turkeys hatch in a hostile 
environment, and are exposed for several hours to heat stress and potential pathogenic bacteria in 
the hatcheries. Increased stress along with the potential abundance of pathogens in the hatching 
cabinet leads to ideal conditions for pathogen colonization. It is generally accepted that the natural 
route of transmission of zoonotic pathogens such as Salmonella, is fecal-oral (White et al., 1997; 
Galanis et al., 2006). However, published studies have also suggested that airborne transmission 
of Salmonella in poultry is possible (Wathes et al., 1988; Baskerville et al., 1992; Leach et al., 
1999; Fallschissel et al., 2009). Understanding the anatomical and immunological defenses of the 
avian respiratory tract helps to clarify this issue. Architecture of the avian respiratory tract is an 
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important component to susceptibility and resistance to infectious agents. In day old chickens and 
turkeys, no or very few infiltrating lymphocytes are seen in the primary bronchi region (Fagerland 
and Arp, 1990; Smialek et al., 2011) and it isn’t until 3-4 weeks of age the lymphoid nodules are 
developed at these locations (Fagerland and Arp, 1993; Drolet et al., 2010). During the following 
week, the number of IgG, IgA or IgM-producing cells continues to increase, however, the 
bronchial-associated lymphoid tissue (BALT) is not mature until chickens are 6–8 weeks old 
(Bienenstock, 1980; Bienenstock and McDermott, 2005; De Geus, 2012). Hence, commercial 
neonate poultry are extremely susceptible to airborne pathogens, regardless of respiratory or 
enteric bacteria (Arshad et al., 1998). In support of these findings, our laboratory has recently 
showed that transmission by the fecal-respiratory route is a viable portal of entry for Salmonella 
(Kallapura et al., 2014a,b,c). This mode of infection could explain some clinical expression of 
relatively low-dose infectivity under field conditions in relation to the high oral challenge dose 
that is typically required for infection through the oral route in laboratory studies. This also 
supports previous studies demonstrating fan driven spread of Salmonella within the hatching 
cabinet and hatchery incubators (Hashemzadeh et al., 2010).  
Over a century ago, Eli Metchnikoff proposed the ground-breaking idea to ingest viable 
bacteria to endorse health (Metchnikoff, 1908). This concept is more appealing today, since 
antimicrobial resistant bacteria have become a problem in many countries (Kiser, 1976; Dahiya et 
al., 2006; Teillant and Laxminarayan, 2015). The imminent ban of antibiotics in animal feed 
creates a challenging scenario for expansion of alternative prophylactics (Parker, 1990; Dahiya et 
al., 2006; You and Silbergeld, 2014). Probiotics and direct-fed microbials are becoming accepted 
as one of the best tools on keeping gastrointestinal health and promoting performance in poultry 
raised without antibiotics (Dominguez-Bello and Blaser, 2008). In addition to improving intestinal 
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microbial balance, metabolism, and gut integrity (Isolauri et al., 2002; Salminen and Isolauri, 
2006), studies have also shown that probiotics have anti-inflammatory (Borchers et al., 2009; Lyte, 
2011), anti-oxidant (Farnell et al., 2006; Tao et al., 2006; Zareie et al., 2006; Segawa et al., 2011; 
Howarth and Wang, 2013), and enhacing barrier integrity properties (Yu et al., 2012). 
Furthermore, several researchers have confirmed benefits of probiotics on innate immunity 
(Alvarez-Olmos and Oberhelman, 2001; Vanderpool et al., 2008; Molinaro et al., 2012) as well as 
humoral immunity (Arvola et al., 1999; Haghighi et al., 2006; Howarth and Wang, 2013).  
FloraMax®-B11 is a defined lactic acid bacteria (LAB) probiotic culture that has 
demonstrated an accelerated development of normal microflora in chickens and turkeys. It 
provides increased resistance to Salmonella spp. infections (Farnell et al., 2006; Higgins et al., 
2007, 2008, 2010; Vicente et al., 2007; Menconi et al., 2011, 2013; Tellez et al., 2012; Biloni et 
al., 2013; Delgado et al., 2014), reduces idiopathic diarrhea in commercial turkey brooding houses 
(Higgins et al., 2005), as well as increased performance and reduced costs in poultry (Torres-
Rodriguez et al., 2007; Vicente et al., 2008). However, no studies have been evaluated for 
administration of FloraMax®-B11 in ovo, and the only practical and reliable way to evaluate this 
route of administration, would be mixing it with the diluent of the Marek’s disease (MD) vaccine. 
Hence, the objective of the present study was to evaluate the effect of the in ovo administration of 
FloraMax®-B11 on MD vaccine herpesvirus of turkeys (HVT) protective efficacy, hatchability, 
microbiota composition, morphometric analysis, and SE infection in chickens. 
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MATERIAL AND METHODS 
Probiotic Culture  
FloraMax®-B11 (Pacific Vet Group USA Inc., Fayetteville, AR) is a defined probiotic culture 
derived from poultry gastrointestinal origin that contains proprietary strains of LAB. 
In ovo evaluation of FloraMax®-B11 on Marek´s disease HVT vaccine  
Chickens and Viruses. Maternal-antibody-negative, White Leghorn 15I5x71 chickens were used 
in these experiments (Bacon et al., 2000). These MD-susceptible chickens were from an SPF 
breeding flock with no MD vaccinations or exposure that tested negative for MDV antibodies, 
exogenous avian leukosis virus, and reticuloendotheliosis virus by routine surveillance testing. All 
birds were housed in negative-pressure Horsfall-Bauer isolators, and experiments were conducted 
following approval by the USDA Avian Disease and Oncology Laboratory (ADOL) Animal Care 
and Use Committee. Viruses were propagated on primary duck embryo fibroblasts (DEF) 
maintained in Leibovitz L-15 medium plus McCoy 5A medium (1:1), supplemented with 2.5% 
bovine serum and antibiotics (Witter et al., 1980). In experiment 1, chickens were challenged with 
the MDV strain 583, a virulent (v) strain. In experiment 2, chickens were challenged with MDV 
strains Md5 or 612, both very virulent (vv). HVT is a commercial vaccine, and was prepared and 
utilized as recommended by the manufacturer. 
Experimental Design 
Experiment 1. Chicks were randomly distributed into four groups (each with 17 birds) in two 
independent trials: 1) HVT vaccinated in ovo and no MDV challenge; 2) HVT + FloraMax®-B11 
vaccinated in ovo and no MDV challenge; 3) HVT vaccinated in ovo and challenged with MDV; 
4) HVT + FloraMax®-B11 vaccinated in ovo and challenged with MDV. MD vaccine was 
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administered in ovo at the manufacturer recommended dosage either alone or with FloraMax®-
B11 (104 cfu). Birds were monitored until 8 wk of age, then humanely euthanized and evaluated 
for MD incidence. Chickens were considered MD positive if peripheral nerve enlargements, 
tumors, or both were present at necropsy. When enlarged nerves or gross tumors were in question, 
tissue samples were collected and processed for microscopic evaluation. Chicks that died during 
the first wk of placement were considered nonspecific chick mortalities and were excluded from 
the experiment.  
Experiment 2. The identical conditions were used as described for experiment 1 except that MDV 
strains Md5 and 612 were used instead of strain 583A and the experiment included only one trial.  
Effect of in Ovo Application of FloraMax®-B11 on Hatchability and Microbiota Composition.. 
Experiment 3 consisted of three independent trials. Eighteen-day-old embryos were obtained from 
Cobb-Vantress (Siloam Springs, AR). In each trial, eggs were candled and inoculated with either 
saline or 104 cfu of FloraMax®-B11 via in ovo injection into the amnion. The two treatment groups 
were placed in separate hatchers to avoid cross contamination. On d 21, chicks were pulled from 
hatchers and hatchability was determined. In each trial, 12 chickens from each group were 
humanely euthanized to evaluate gastrointestinal composition on selective media as describe 
below.  
Enumeration of Bacteria. For trial 1, the whole gut (ventriculus to cecum) was aseptically 
removed. For trials 2 and 3, the fore gut (ventriculus to Meckel’s diverticulum) and hind gut 
(Meckel’s diverticulum to cecum) were removed separately. Sections were collected into sterile 
bags and homogenized. Samples were weighed and 1:4 wt/vol dilutions were made with sterile 
0.9% saline. Ten-fold dilutions of each sample, from each group were made in a sterile 96 well 
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Bacti flat bottom plate and the diluted samples were plated on two different culture media; to 
evaluate total number of LAB in Man Rogosa Sharpe (Difco™ Lactobacilli MRS Agar VWR cat. 
no. 90004-084, Suwanee, GA 30024); total coliforms in MacConkey (VWR cat. no. 89429–342, 
Suwanee, GA 30024).  
 
Evaluation of in Ovo Administration of FloraMax®-B11 on Body Weight, Salmonella enteritidis 
Recovery, and Morphometric Analysis in Broiler Chickens. In experiment 4, the challenge 
organism used in all experiments was a poultry isolate of Salmonella enterica (SE) serovar, 
Enteritidis, bacteriophage type 13A, obtained from the USDA National Veterinary Services 
Laboratory, Ames, IA. This isolate was resistant to 25 µg/mL of novobiocin (NO, cat. no. N-1628, 
Sigma, St. Louis, MO 63103) and was selected for resistance to 20 µg/mL of nalidixic acid (NA, 
cat. no. N-4382, Sigma) in our laboratory. For the present studies, 100 µL of SE from a frozen 
aliquot was added to 10 mL of tryptic soy broth (cat. no. 22092, Sigma) and incubated at 37°C for 
8 h, and passed three times every 8 h to ensure that all bacteria were in log phase. Post-incubation, 
bacterial cells were washed 3 times with sterile 0.9% saline by centrifugation at 1,800 × g for 10 
minutes, reconstituted in saline, quantified by densitometry with a spectrophotometer (Spectronic 
20D+, Spectronic Instruments Thermo Scientific, Waltham, MA 02451), and diluted to an 
approximate concentration of 108 cfu/ml. Concentrations of SE were further verified by serial 
dilution and plating on brilliant green agar (BGA, cat. no. 70134, Sigma) with NO and NA for 
enumeration of actual cfu used to challenge the chickens. 
In this trial, 300 eighteen-day-old embryos were received from Cobb-Vantress. At d 18, 
eggs were candled and inoculated with either saline or 104 cfu FloraMax®-B11 via in ovo injection 
into the amnion. The two treatment groups were placed in separate hatch cabinets placed in 
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separate rooms to avoid cross contamination. On d 21, chicks were pulled from hatchers to measure 
hatchability. All chickens were then orally gavaged with SE on d of hatch (~104 cfu/chick). 
Twenty-four hours post inoculation (PI), twenty chickens were euthanized with carbon dioxide 
asphyxiation to determine SE intestinal colonization as described below. From these chickens, 5 
samples were also taken to determine intestinal morphometric analysis as described below. BW 
was determined at d 1, 3, and 7. Chickens were provided ad libitum access to water and a balanced 
unmedicated corn-soybean diet meeting the nutrition requirements of poultry recommended by 
NRC (1994). All animal handling procedures were in compliance with Institutional Animal Care 
and Use Committee at the University of Arkansas. 
Salmonella Recovery  
Ceca-cecal tonsils (CCT) were homogenized and diluted with saline (1:4 by wt/vol) and tenfold 
dilutions were plated on BGA with NO and NA, incubated at 37°C for 24 h to enumerate total SE 
colony forming units. Following plating to enumerate total SE, the CCT samples were enriched in 
double strength tetrathionate enrichment broth and further incubated at 37°C for 24 h to enrich. 
Following this, enrichment samples were plated on BGA with NO and NA and incubated at 37°C 
for 24 h to confirm presence/absence of typical lactose-negative colonies of Salmonella.  
 
Intestinal Morphological Analysis 
 For enteric morphometric analysis ileum and duodenum samples were collected (n = 5). A 1-cm 
segment of the midpoint of the duodenum and the distal end of the lower ileum from each bird was 
removed and fixed in 10% buffered formaldehyde for 48 h. Each of these intestinal segments was 
embedded in paraffin, and a 5-μm section of each sample was placed on a glass slide and stained 
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with hematoxylin and eosin for examination under a light microscope. All morphological 
parameters were measured using the ImageJ software package (http://rsb.info.nih.gov/ij/). Ten 
replicate measurements for each variable studied were taken from each sample, and the average 
values were used in statistical analysis. Villus length (VL) was measured from the top of the villus 
to the top of the lamina propria (Yitbarek et al., 2013). Crypt depth was measured from the base 
upward to the region of transition between the crypt and villus (Biloni et al., 2013). Villus width 
(VW) was measured at the widest area of each villus, whereas the villus:crypt ratio was determined 
as the ratio of villus height (VH) to crypt depth. Villus surface area (VSA) was calculated using 
the formula (2π)(VW/2)(VL), (Sakamoto et al., 2000). 
 
Statistical Analysis 
All data were subjected to one-way analysis of variance as a completely randomized design using 
the GLM procedure of SAS (SAS Institute, 2002). Data is expressed as mean ± standard error. 
Significant differences among the means were determined using Duncan’s multiple-range test at 
P < 0.05. MDV as well as SE incidence data were expressed as positive/total chickens (%), and 
the percent recovery of SE was compared using the chi-squared test of independence, testing all 
possible combinations to determine the significance (P ≤ 0.001) for these studies (Zar, 1984). 
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RESULTS 
This study addressed three major concerns: 1) whether in ovo administration of FloraMax®-B11 
mixed with MD vaccine would negatively impact vaccine efficacy, 2) the effect of in ovo 
administration on hatchability and microbiota composition and 3) the impact on Salmonella 
infections in broiler chickens.  Experiment 1 consisted of two independent replicates to determine 
if there was any difference when birds were vaccinated in ovo with HVT only or with HVT + 
FloraMax®-B11 followed by challenge with vMDV. The results of the in ovo evaluation of 
FloraMax®-B11 on HVT vaccine efficacy in experiments 1 and 2 are summarized in Table 1. In 
both experiments, there was no significant difference between % MD in birds vaccinated with 
HVT alone or HVT + FloraMax®-B11, although numerical differences between treatment suggest 
that probiotics may have slightly improved protection immunity in birds challenged with MDV 
strain 583. This benefit was not apparent when we used vvMDV strains (Md5 and 612) in 
experiment 2 (Table 1). 
The effect of in ovo administration of the probiotic FloraMax®-B11 on hatchability in 
experiment 3 is displayed in Table 2. There was no significant difference in hatchability between 
embryos administered probiotics or the controls. The results of the effect of in ovo application of 
FloraMax-B11® on microbial composition in the gastrointestinal tract of hatching broiler chickens 
in experiment 3 are summarized in Table 3. In trials 1 and 3, chickens treated with FloraMax®-
B11 showed a significant reduction in coliforms recovery when compared with saline control 
group at d of hatch. In trial 2, the treated group had numerically lower recovery than the control 
group and in fact had reduced gram negatives to non-recoverable numbers. With the exception of 
hindgut in trial 2, a significant increase in the total number of LAB was observed in probiotic 
group when compared with saline treated group (Table 3).  
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The results of in ovo administration of FloraMax®-B11 on hatchability, BW and SE 
recovery in broiler chickens of Experiment 4 are summarized in Table 4. In this experiment, no 
significant changes were observed in hatchability or the BW of the neonates when they were 
removed from the hatching cabinets; however, a significant increase in BW was observed in 
chickens that received the probiotic when compared with saline control groups on d 3 and 7 (Table 
4). Interestingly, chickens that received the probiotic, showed a significant reduction in the 
incidence and total SE cfu numbers recovered from CCT when compared with saline control 
chickens (Table 4). 
The results of the effect of in ovo application of FloraMax®-B11 on morphometric analysis 
of the gastrointestinal tract of hatching broiler chickens of experiment 4 are summarized in Table 
5. A numerical increase in VH, VW, and VSA was observed in the treated group when compared 
to the controls for the duodenum. Nevertheless, embryos that received the probiotic showed a 
significant increase in the villus:crypt depth ratio when compared with saline control group. In the 
ileum, there was a significant increase in VH, VSA, and crypt depth in the probiotic treated group 
when compared to the control group.  
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DISCUSSION 
MMD is a lymphoproliferative disease of domestic chickens caused by an oncogenic α-herpesvirus 
(Churchill and Biggs, 1967; Calnek, 2001). The disease is associated with lymphomas, neurologic 
manifestations, and immune suppression (Calnek, 2001). Without a question, MD has been a major 
concern to the poultry industry for over half a century (Nair, 2005), and the modern poultry 
industry as we know it today, would not exist without the development of MD vaccines (Baigent 
et al., 2006; Gimeno, 2008; Parvizi et al., 2010; Silva et al., 2010; Dunn and Silva, 2012). The 
virus is so abundant and stable in the environment, that vaccination at the hatchery is the only 
effective method to control MD in commercial flocks (Witter et al., 1980, 2005; Baigent et al., 
2006; Dunn et al., 2010). Due to the significant economic and immunosuppression impact, modern 
commercial chickens are vaccinated before they leave the hatchery.  
Although, we have reported the benefits of spray application of FloraMax®-B11 in the 
hatcheries (Wolfenden et al., 2007), this is the first report of in ovo application of this defined 
probiotic, mixed with HVT vaccine simultaneously. One of the two major concerns we addressed 
in this study was whether in ovo administration of FloraMax®-B11 mixed would negatively affect 
MD vaccine protective efficacy. The results of experiments 1 and 2, demonstrated that there was 
no negative impact and even possibly a small improvement of the probiotic depending on the MDV 
challenge strain. As far as we are aware, this is the first report showing the possibility of combining 
a probiotic with an in ovo MD vaccine showing no negative effect. The other major concern with 
in ovo application of FM was on broiler hatchability, but in every trial conducted the probiotic also 
showed no negative effects on hatchability. 
In the present study, it was remarkable to observe that embryos, which received the 
probiotic before hatch, had a significant reduction in coliforms when compared with saline treated 
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chickens (Table 3). Although there is extensive evidence demonstrating that this particular 
probiotic is able to control Salmonellae infections in poultry in both, laboratory or commercial 
conditions (Farnell et al., 2006; Higgins et al., 2007, 2008, 2010; Vicente et al., 2007; Menconi et 
al., 2011, 2013; Tellez et al., 2012; Biloni et al., 2013; Delgado et al., 2014). This current study 
further validated the probiotics efficacy via in ovo administration by reducing the recovery of SE 
when chickens were challenged at d of hatch and cultured 24 h later (Table 4). These results are in 
agreement with the work of De Oliveira et al. (2014) who demonstrated that in ovo colonization 
with probiotic could become an important method to reduce Salmonella and other intestinal 
bacterial infections in poultry.  
In experiment 4, the significant increase in BW in treated chickens at d 3 and 7 (Table 4), 
were associated with significant morphometric changes in the duodenum and ileum observed at d 
1 (Table 5). It is likely that the higher BW in the probiotic treated group was due to the increase 
VH, leading to more VSA leading to better nutrient absorption. These results are quite impressive, 
when a newly hatched modern d broiler chick increases its BW by 25% overnight and 5000% by 
5 wk, to 2kg (Choct, 2009). Similarly, it is also important to consider the productive life of broiler 
chickens. The full genetic potential of modern chickens starts at conception and the first 21 d of 
embryo development. During this period, variables as temperature or oxygen are important and 
any problem related to them could cause a big impact later in life. Hence, the 21 d of 
embryogenesis plus the first 7 d of life of the chicken could potentially represent between 50% to 
74% of the life of a commercial broiler chicken, depending on the time they are slaughtered (56 or 
77 d) (Cherian, 2011). Therefore, earlier administration of probiotics to embryos can have a 
profound impact on growth and overall health of the birds.  
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In summary, the results of the present study suggest in ovo administration of FloraMax®-
B11 does not negatively affect HVT vaccine efficacy or hatchability of the chickens, and improves 
BW and intestinal integrity during the first 7 d of life while decreasing SE intestinal load in broiler 
chickens. Studies to evaluate these effects under commercial conditions are currently underway.  
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Table 1. 
In ovo evaluation of FloraMax®-B11 on HVT Marek´s vaccine virus stability and incidence of 
disease.  
 HVT only HVT + FloraMax®-B11 
Experiment 1 (Trial 1)   
Unchallenged  0/15 (0 %) 0/17 (0 %) 
vMDV challenge (583) 3/17 (18 %) 0/17 (0 %) 
Experiment 1 (Trial 2)   
Unchallenged  1/16 (6 %) 0/17 (0 %) 
vMDV challenge (583) 4/15 (27 %) 3/16 (19 %) 
Experiment 2    
Unchallenged  0/17 (0 %) 0/17 (0 %) 
vvMDV challenge (Md5) 10/17 (59 %) 9/17 (53 %) 
vvMDV challenge (612) 11/17 (65 %) 13/17 (76 %) 
Marek’s disease HVT vaccine was administered in ovo at manufacturer labeled dosage alone or 
with FloraMax®-B11 (104 cfu/g). MDV challenge was administered at 5 d of age using 500 pfu 
vMDV strain 583 in experiment 1, or 500 pfu vvMDV strains Md5 or 612, respectively. Birds 
were monitored until 8 wk of age, then euthanized and measured for MD incidence. P > 0.05 
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Table 2. 
 Effect of in ovo application of FloraMax®-B11 on hatchability.  
Treatment   Trial 1  Trial 2  Trial 3 
Saline 137/140 (97.8%) 46/48 (95.8%) 144/145 (99.3%) 
FloraMax®-B11 121/121 (100%) 47/48 (97.9%) 142/150 (94.6%) 
 
At d 18 eggs were candled and inoculated with either 0.9% saline or FloraMax®-B11 via in ovo 
injection into the amnion. On d 21, chicks were pulled from hatchers and hatchability was 
determined, P > 0.05. 
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Table 3. 
Effect of in ovo application of FloraMax®-B11 on microbial composition in the gastrointestinal tract of hatching broiler chickens.  
Selective media  
and experimental 
groups 
Trial 1 
 
Whole gut 
Trial 
 
Fore gut 
2 
 
Hind gut 
Trial 
 
Fore gut 
3  
      
Hind gut 
Total coliforms/g 1      
 
Saline 
 
 
8.24 ± 0.27 
 
0.8 ± 0.5 
 
1.6 ± 0.8 
 
4.06 ± 0.52 
 
8.54 ± 0.24 
FloraMax®-B11 0.92 ± 0.48 * 0.0 ± 0.0 0.0 ± 0.0 0.05 ± 0.01 * 0.0 ± 0.0 * 
Total LAB/g 2      
Saline 
 
8.70 ± 0.26 4.90 ± 0.5 7.7 ± 0.40 0.00 ± 0.0 0.84 ± 0.60 
FloraMax®-B11 6.43 ± 0.94 * 6.20 ± 0.50 * 7.9 ± 0.40 4.33 ± 0.50 * 6.00 ± 0.31 * 
 
At d 18 eggs were candled and inoculated with either saline or FloraMax®-B11 via in ovo injection into the amnion. On d 21, chicks 
were pulled from the hatchers and for experiment 1, the whole gut (ventriculus to cecum) was aseptically removed. For experiment 2 
and 3 the fore gut (ventriculus to Meckel’s diverticulum) and hind gut (Meckel’s diverticulum to cecum) were removed separately.  
1 Samples were plated on MacConkey agar to evaluate total coliforms. 
2 Samples were plated on MRS agar to evaluate total lactic acid bacteria. 
Data is expressed as Log10 CFU/gram  
Data is expressed as mean ± standard error. *Superscripts within columns for each plate indicate significant difference at P < 0.05, n = 
12.  
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Table 4. 
Evaluation of in ovo administration of FloraMax®-B11 on hatchability, body weight, and Salmonella enteritidis recovery in broiler 
chickens.  
Treatment Hatchability Day 1 
BW (g) 
Day 3 
BW (g) 
Day 7 
BW (g) 
SE incidence 
Ceca–cecal tonsils 
24 h PI 
Log10 SE/g of 
ceca content 
24 h PI  
Saline  148/150 (98.6 %)  49.13 ± 0.30 a 62.53 ± 0.81 b 132.89 ± 3.06 b  20/20 (100 %)  7.13 ± 1.01 a 
FloraMax®-B11  142/150 (94.6 %) 49.72 ± 0.36 a 65.42 ± 0.77 a 144.98 ± 3.02 a  9/20 (45 %) *  5.45 ± 1.25 b 
 
At d 18 eggs were candled and inoculated with either saline or FloraMax®-B11via in ovo injection into the amnion. On d 21, chicks 
were pulled from the hatchers and were challenged with Salmonella Enteritidis (SE) on d of hatch ~104 cfu/chick. Incidence data is 
expressed as positive/total chickens (%) at 24 h post inoculation (PI), asterisk indicate significant differences P < 0.001, n = 20/group. 
Log10 SE/g of ceca content is expressed as mean ± standard error. 
abSuperscripts within columns indicate significant differences P < 
0.05, n = 12/group. 
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Table 5. 
Evaluation of in ovo administration of FloraMax®-B11 on morphometric analysis of the gastrointestinal tract of hatching broiler 
chickens.  
 Villus height (µm) Villus width (µm) 
Villus surface 
 area (mm2)* 
Crypt depth (µm) VH:CD ratio** 
Duodenum 
     
Control 223.39 ± 3.55 a 36.01 ± 0.72 a 25.39 ± 0.69 a 49.92 ± 1.15 a 4.74 ± 0.14 b 
FloraMax®-B11 234.58 ± 5.19 a 36.14 ± 0.60 a 26.87 ± 0.86 a 39.93 ± 0.88 b 6.09 ± 0.19 a 
 
Ileum 
     
Control 148.09 ± 4.26 b 27.42 ± 0.86 a 13.10 ± 0.67 b 36.70 ± 1.04 b 4.16 ± 0.12 a 
FloraMax®-B11 176.77 ± 5.50 a 29.01 ± 0.78 a 16.47 ± 0.80 a 40.55 ± 1.19 a 4.59 ± 0.21 a 
 
a,b Means with different superscripts within the same column differ significantly (P < 0.05). 
* Villus surface area: [2π × (villus width/2) × (villus height)] 
** Villus height (VH) to crypt depth (CD) ratio 
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Chapter IV 
Conclusion 
 This study evaluated the early administration of a probiotic, which could potentially be an 
alternative to antibiotics, for use in the poultry industry. In the study discussed in Chapter III, a 
commercial probiotic was administered in ovo and evaluated. We assessed if the mixture of the 
probiotic and the Marek’s vaccine had an effect on the ability of the vaccine to protect against 
Marek’s Disease. The results showed that the administration of the mixture of the vaccine and 
the probiotic had no negative effect on the protectiveness of the vaccine when compared with 
birds administered the vaccine only. In this study, we also evaluated hatchability and bacterial 
recovery from the gastrointestinal tract. The in ovo administration of the probiotic had no effect 
on hatchability and significantly reduced coliforms within the gastrointestinal tract at hatch. 
Lastly, we evaluated the ability of the probiotic to reduce Salmonella recovery and increase BW 
post in ovo inoculation. 24 h post Salmonella challenge we observed a significant reduction in 
Salmonella recovery and incidence, along with a significant increase in BW at days 3 and 7. 
Which could be a result of the increased villus surface area observed in the ileum of the probiotic 
treated group. This study shows a favorable administration technique and probiotic that could 
allow for early colonization of beneficial microflora and increased efficiency.     
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